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Medicines Regulation in West Africa: Current State and Opportunities
O. Sopein-Mann 1, Z. Ekeocha 2, S. Byrn 3, K. Clase 4

ABSTRACT
Ndomondo-Sigonda et al. (2017) observed that there is scarcity of information on human resources (personnel
devoted to regulation of medicines) in the domain of medicines regulation in the sub-Saharan Africa (SSA). The
published information on medicines regulation by the National Medicines Regulatory Authorities (NMRAs) in the
Economic Community of West African States (ECOWAS) region are no longer current and consistent with the
current realities in the NMRAs. In order to reveal this occurrence, show the trends that exist over the years and
make appropriate recommendations, data were collected and compared from 2005, 2010 and 2017 research reports on seven regulatory features of the fifteen Members States of ECOWAS. The results show that there was
missing information per regulatory feature and country. There was also an overall increasing trend in the number
of NMRAs in the region that showed progress with respect to the measured regulatory features - Autonomy (Authority and Legal form), Marketing Authorization), GMP inspection, Quality Control, Quality Management System,
Information Management System and Harmonization and International cooperation. People of Africa have a valuable story to tell as it relates to medicines regulation. This report is written by a West African from the perspective
of a West African involved in the study and practice of medicines regulation by the NMRAs in the ECOWAS.
Keywords: medicines, regulation, marketing authorization, Good Manufacturing Practice (GMP), National Medicines Regulatory Authorities (NMRAs); Economic Community of West African States (ECOWAS), West African
Health Organization (WAHO), West African Medicines Regulatory Harmonization (WA-MRH)

1. INTRODUCTION
Early History on the Basis of Medicines Regulation
Griffin (2004) narrates the history of the foundation of
modern medicines regulation, which started with
Mythridatum and the related product Theriac as the
universal panacea in the second century BC and first
century AD, respectively. These two products were
thought to be effective for all illnesses, but if they did
not work as expected, bad quality ingredients and
poor manufacturing were blamed. This, then, called
for the need to ensure quality of the ingredients, establish standard formulation for these products and
ensure competence of the manufacturers.

For this reason, Mythridatium and Theriac were produced in the public space as it was generally accepted
that failure was due to the probable misdemeanor of
the manufacturers (pharmacists) (Griffin, 2004). However, in 1745, doubts arose regarding their efficacy
and safety due to possible interactions among the ingredients used. By 1746, the products were removed
from London Pharmacopoeia; and in 1799, a decree
was enacted to convene a group of elite physicians
who examined all products before they were released
to the public.
From 1540, one of the earliest laws on drug control
was established, which permitted the inspection of the
premises and wares of the apothecaries; and to bring
upon them appropriate sanctions if found guilty of
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non-compliance (Griffin, (2004). The statute specifically permitted the appointment of inspectors, inspection of the apothecaries’ stores, destruction of defective and corrupt wares and drugs not suitable for human consumption and charging of higher fees when
inspections were excused or refused.
In order to control the quality and standard of mythridatium and theriac, an official and obligatory document was produced called pharmacopoeia, derived
from two Greek words, pharmakon (drugs) and poiia
(making). The first pharmacopoeia in Europe was
published for the apothecaries in Florence in 1498
and, subsequently, in other cities such as Barcelona
in 1535, Nuremberg in 1546 and London
(pharmacopoeia Londinensis) in 1618 (Griffin, 2004).
The Pharmacopoeia helped establish the standard
formulation of mythridatium and theriac which made
inspection easier and lifted the limit of the manufacture of the products by one apothecary. During the
London plague of 1650, three apothecaries were approved to manufacture mythridatium and theriac in
London (Griffin, 2004).
The Food and Drug Legislation came into existence
in 1872 and eradicated all of the existing laws and
statutes which had allowed the Censors of the College of Physicians and Wardens of the Worshipful Society of Apothecaries to carry out their activities to
serve as the basis of modern day medicines regulation (Griffin, 2004). Mythridatium and Theriac were the
motivation for medicines regulation, being the first
medicines to be challenged on the bases of efficacy
and drug interaction (Griffin, 2004).
Griffin (2004) also stated that the Medical and Physical Journal, in 1799, proposed that no product should
be advertised and sold to the public without the examination, analysis and declaration of quality by the college of physicians. This is 170 years before the Medicines Act of 1968 in the United States of America.
Rago and Santoso (2008), cited that the history of regulation of medicines dated as far back as 1540 and
the history of pharmacopeia in Europe can be traced
to the 16th century. However, the accelerated evolution of regulation of medicines came about by some
unfortunate events, such as the poisoning by diethylene glycol, where hundreds lost their lives after taking
the contaminated mixture and the thalidomide
disaster in Europe, where thousands of babies were
born deformed, (Rago & Santoso, 2008). After the
Thalidomide disaster, several directives (65/65/EEC),
laws, regulations and administrative actions arose.
Acts in Europe and in the United States of America on
regulation of medicines, requirements on current
Good Manufacturing Practices (CGMP) and official
registration of drug establishments in the USA also
came into existence (Rago & Santoso, 2008).

1930 - United States Food and Drug Administration (USFDA)The history of medicines regulation in
the United States of America is similar to the UK and
Europe. An event in 1906 led to a law which prohibited misbranded and adulterated foods, drinks and
drugs in interstate commerce. The law was enforced
by the Bureau of Chemistry in the Department of Agriculture, which later became the Food and Drug Administration in 1930. In 1938 the Federal Food, Drug
and Cosmetic (FD&C) Act created new provisions for
manufacturers to demonstrate that a drug was safe
before it could be marketed (USFDA, n.d.). The laws
of the United States of America were improved, as
occasions demanded. The latest law came in 2003,
when an authority under the Pediatric Research Equity Act was granted to the FDA to require sponsors
to conduct clinical research for new drugs in pediatric drug applications (USFDA, n.d.).
Ten years after the Council Directive 65/65/EEC in
Europe, the idea of harmonization was introduced.
The Mutual Recognition Procedure began in 1975
and the Central Procedure, in 1987, to ensure a common market for medicines in Europe (Rago & Santoso, 2008).
Simultaneously, harmonization was expanding beyond Europe. Collaboration started during a discussion among officials from Japan, the European Union
and the United States of America during the International Conference of Drug Regulatory Authorities
(ICDRA), organized by the World Health Organization
(WHO) in 1989. These discussions established the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in Paris in 1990 (Rago &
Santoso, 2008), where dossiers of new and innovative medicines would be evaluated to ensure quick access to the people who needed them most.
Since it is mostly generic medicines that flood many
low- and medium-income countries (LMIC), the World
Health Organization (WHO) played a supportive role
in national, regional, inter-regional and international
harmonization to ensure a fast-reaching, international
consensus on quality, safety and efficacy standards
in order to accelerate entry into the market of quality
new and generic medicines.
2003 – The Establishment of the UK Medicines
and Healthcare Products Regulatory Agency
(MHRA)
According to Breckenridge (2004), the Medicines and
Healthcare Products Regulatory Agency (MHRA) was
established in the United Kingdom by the merger of
the Medicines Control Agency (MCA), which was in
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charge of the medicines regulation, and the Medical
Devices Agency (MDA), which regulated and controlled the Medical Devices. This merger forced the
UK to join the League of Nations with the USA and
Europe, where both medicines and medical devices
are housed under one organization. The functions of
the two erstwhile Agencies (MCA and MDA), became
the scientific and organizational reasons behind the
formation of MHRA in the UK as well as highlighted
the possible challenges it would face.
Some of the organizational challenges, faced by the
MHRA, mentioned by Breckenridge (2004), were
premised on the co-location of the two agencies, as
they were located in different sites. Co-location was
necessary to unify an organization, to ensure compatibility of the Information Technology (IT) systems of
the two organizations and to address the cultural and
scientific challenges of bringing together large and
small organizations with different backgrounds. Additional challenges were the need for MHRA to ensure
a proactive and effective communication with both
stakeholders (patients, healthcare professionals, industries and government) and staff. There was the
need to work more closely with other newly established agencies in the UK, whose responsibilities considerably overlap with MHRA. As new countries joined
the EU, the need grew for MHRA to provide support
for the then London-based EMEA. The EMEA helped
new countries build their regulatory medicines and
medical devices capacities. It also worked with the EU
to ensure that a uniform standard of approval existed
across Europe for the new Notified Bodies in the EU
that approved medical devices for UK market
(Breckenridge, 2004).
The scientific challenges MHRA faced at that time
were: tissue engineering and its regulation, which require the combination of human-derived cells; mechanical support and molecular signaling processes
(pharmacology and medical devices) for the treatment
of individual patients; pharmacogenetics in medicines. In addition, MHRA faced the challenge of increased pressure to have a high percentage of adverse reaction reports in its database, while carrying
out exhaustive and effective Post Market Surveillance
(PMS) in order to ensure patient safety. The MCA had
been criticized for not having exhaustive listings of adverse reactions. MHRA now strives to capture quality
rather than quantity of adverse reaction reports.
2005 - Medicines Regulation in Africa
The first plan ‘Mother plan’ for medicines regulation in
Africa was developed in 2005 during the 1st African
Medicines Regulatory Authorities Conference (AMRAC) that was held in Addis Ababa, Ethiopia and was
documented as a WHO/AFRO’s final report of the
medicines regulation cross-sectional view in Africa in

2005. It became the Strategic Plan from 2006-2010,
which identified the existing problems of regulation of
medicines in 2005 in Africa. It also suggested the strategic approach/interventions and activities needed to
be implemented in order to facilitate the required
growth of medicines regulation in Africa.
The regulatory landscape was characterized by the
following, among others: ineffective licensing system,
weak product registration, poor inspection practices,
inadequate access to quality control laboratories, inadequate market control, non-existence of pharmacovigilance and control of promotion, lack of clinical
trials oversight, inadequate communication and information exchange system, lack of transparency and
accountability and conflict of interest. According to the
final report, of the 46 sub-Saharan African countries,
7% of the National Medicines Regulatory Authorities
(NMRA) had moderately developed medicine regulatory capacity, 63% had minimal capacities, while 30%
did not have an NMRA in place. These problems were
not improving much despite the efforts of WHO, or
other international organizations and donor communities, because of the absence of government support,
lack of adequate number of trained and qualified staff,
high staff turn-over due to low salaries and lack of incentives, inadequate and unsustainable funding of the
NMRAs and weak infrastructure (World Health Organisation,
2005).
In order to solve the problems, the 1st African Medicines Regulatory Authorities Conference (AMRAC)
convened representatives from the National Medicines Agencies, regional blocks in the sub-Sahara Africa and members of harmonization initiatives such as
ICH, CEAC and SADC. After extensive presentation
of the situation and group discussion, the group documented the strength, probable weakness and recommendations, which led to a five-year plan towards
improving the scenario. Some of the weaknesses
highlighted during the meeting were:
•

weak Medicines Regulatory Authorities
(MRAs) with limited human and financial resources;

•

parallel and overlapping harmonization initiatives;

•

lack of structures to coordinate harmonization
initiatives, e.g. secretariat;

•

inadequate exchange of information and experiences;

•

lack of a common understanding of the true
meaning and vision/goals of harmonization;

•

lack of political commitment;
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•

lack of commitment from MRAs;

•

lack of sustainable funding.

The recommended steps to carry out harmonization
were:
•

build trust and commitment among technical
people towards harmonization;

•

secure political commitment and support;

•

carry out situation analysis and identify gaps;

•

define the vision and goals of harmonization;

•

set up administrative structures/secretariat;

•

develop common strategies;

•

develop common technical requirements,
standard, guidelines, procedures;

•

update legislations;

•

exchange information.

2008: A Call for More Effective Regulatory System in Nigeria, West Africa
Akuse et al. (2012) reported the unfortunate incident
which occurred in Nigeria between October and November 2008, where children suffered Acute Kidney
Injury (AKI), and eventually died, due to ingestion of a
particular type of “teething mixture” containing paracetamol and diphenhydramine that was contaminated
with Diethylene Glycol (DEG). Similar incidents occurred in Nigeria in 1999 and in other countries, such
as Bangladesh, India, Haiti, Panama, South Africa
and the United States of America.
Akuse et al. (2012) carried out a multicenter study
where information from hospital records was obtained
to review the clinicopathological features of all children with AKI over a six-month period. The study focused on discovering other means of promptly diagnosing and differentiating children who had Acute Kidney Injury (AKI) due to ingestion of Diethylene Glycol
(DEG) from those who did not in a resource-constrained
environment
such
as
Nigeria.
The results of the study showed that differentiating
AKI caused by ingestion of DEG was difficult, and that
obtaining detailed drug intake history and improved
facilities for hemodialysis for infants, among others,
would assist such differentiation. The authors affirmed
that prevention of future occurrences would require
improved manufacturing practices, effective field drug
testing and international monitoring of raw materials
imported for pharmaceutical manufacturing, which are

all necessary for effective regulatory systems and
structures.
2009-2010, the World Health Organization
The World Health Organization (WHO) carried out a
rapid assessment in 2009-2010 which provided insights into the state of medicines regulation in subSaharan Africa. The assessment was done on 26
countries: eleven in the East Africa, eight in West Africa, two from South Africa and five countries from
Central Africa (WHO, 2010).
The study measured nine core regulatory functions of
National Medicines Regulatory Authorities against the
background of each countries geographical, socioeconomic and pharmaceutical indicators (WHO,
2010). The nine functions that were assessed were
the structure and implementation of regulatory function, marketing authorization, licensing activities,
import control, inspections, quality control, market
surveillance and control of clinical trials.
In each of these core regulatory functions, several sub
components were examined. For example, under the
assessment of the Marketing Authorization, the following components were assessed in order to identify
the gaps:
•

the existence of the legal basis to authorize
medicines for the market;

•

existence of guidance for applicants;

•

standard operating procedures (SOPs) for
assessment;

•

existence of advisory committee;

•

existence of external assessors;

•

full time assessors;

•

Secure filing space;

•

computerized system;

•

existence of list of approved products including Summary of Products Characteristics
(SmPC);

•

recognition of stringent regulatory authorities’
decisions (WHO, 2010).

According to the report (WHO, 2010), 55% of the
eleven countries studies in Eastern Africa had existing
legal basis, 27% had inadequate legal basis, and the
remaining 9% did not have a legal basis to carry out
marketing authorization of medicines. Only 9% had
detailed guidance for applicants with respect to information on format and content of submission requirements. 36% had no SOP for assessment of medicines
dossiers, 9% had written SOPs, while the remaining
countries had SOPs that were either not adequate or
very limited.
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Regarding the existence of the Advisory Committee
for Marketing Authorization, 27% of the East African
countries had an operational advisory committee,
where 45% had an advisory committee that was either
non-operational or non-existent. Advisory committees
of the remaining countries were either just a technical
committee without the correct expertise and did not
have the capacity to review the medicines dossiers.
With respect to the existence of external assessors,
45% had no external assessors, 18% had external assessors, while 27% either had no external assessors
due to lack of funding, or they were limited in capacity.
As per the existence of full-time assessors, 82% of the
countries had an insufficient number. With respect to
secure filing space, it was inadequate in 91% of the
countries. With respect to existence of a computerized system, 36% had none, 55% had either the WHO
Model System for Computer-assisted Drug Registration (SIAMED) in combination with other databases or
stand-alone databases, while 9% had not established
a regulatory system. Regarding the list of approved
products, including SmPC, 91% of the countries had
this list in their systems, but were not updated, published and did not include the SmPC. 9% of the countries were marked ‘not applicable’ because their regulatory system did not exist. 45% of the countries did
not recognize decisions of stringent regulatory NRAs.
9% recognized the decisions of US-FDA, WHO PQ
and EU, while 18% either required or reviewed the
Certificate of Pharmaceutical Product (CPP).
The report (WHO, 2010) also had information on how
the eight countries in West Africa fared:

•

63% of the countries did not have a system of
recognition of the decision of stringent regulatory authorities.

•

13%

requested

the

CPP.

In Southern Africa, where only two countries were assessed, both had adequate legal basis, one had adequate guidance for applicants, the other had no SOP
for assessment. Both countries had Expert Committee or the Advisory Committee, both of the countries
had adequate qualified external assessors but the fulltime assessors were insufficient. Only one of the
countries had secured filing space and a standalone
database instead of the required computerized system of filing. In regards to the list of approved products
with SPC, both had a list either outdated or without
the SPC and both of the countries either recognized
the decision of stringent regulatory authorities or requested decisions from other NMRAs.
In Central Africa, five countries were assessed. 60%
of the countries had adequate legal basis to carry out
Marketing Authorization; 20% had outdated and undetailed guidance for the applicant, 20% had no
guidance. 60% had no SOPs for assessment, 20%
had validated SOPs, while 20% had inadequate
SOPs, with only administrative documents. In 80% of
the countries, an advisory committee existed either
unofficially or not specific to Market Authorization.
60% had no external assessors and 80% had insufficient full-time assessors. None of the five had an adequately secured filing space and only 40% had the
computerized system called SIAMED. The remaining
countries had none or other types, which are not optimal. Regarding the list of approved products, which
included the SPC, only 20% had the list but did not
include the SPC. In respect to the countries that recognize decisions of stringent regulatory authorities,
only 40% requested the CPP.

•

50% had adequate legal basis to carry out
marketing authorization.

•

100% had inadequate guidance for the applicants.

•

100% had inadequate SOPs for assessment.

•

75% had an Advisory Committee.

•

88% of the countries had external assessors.

2014, World Health Assembly 67.20

•

All of the countries had insufficient full-time
assessors.

•

All of them also had inadequate secure filing
space.

•

88% had SIAMED and/or internally networked database or standalone Excel sheets.

•

75% had a list of approved products, but were
not published or updated.

•

None had the SmPC attached to the list of approved products.

On May 24, 2014, the sixty-seventh World Health Assembly (WHA 67.20), Agenda 15.6, which was on
Regulatory System Strengthening for medical products, related with the 2005 Mother Plan on medicines
regulation. The highlights and recommendations of
the resolution were geared towards the various roles
that WHO/AFRO and WHO international could play to
fulfill the elements of the plan, which only they could
fulfill. The resolution highlighted certain points which
accentuated the stance of the World Health Organization to play a pivotal role in support of the establishment and sustainability of an effective regulatory system in developing countries to ensure quality, safe
and efficacious medical products that will strengthen
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the health systems and outcomes (WHO, 2015).
The resolution linked effective regulation to implementation of universal health coverage, achievement
of the Millennium Development Goals 4, reduction of
child Mortality, goal 5, Improvement of maternal
health) and goal 6, Combating HIV/AID, malaria and
other diseases. These goals are now Sustainable Development Goal (SDG) 3 (WHO, 2015) (UNDP, n.d.).
The resolution also linked effective regulation to the
impact of compromised quality, safety and efficacy of
medical products on treatment failure, drug resistance, death and reduction of public trust on the
health system. The role of WHO’s prequalification to
procurement, contributions of the investment of good
proportion of national budgets, and global initiatives
on quality, safe and efficacious medicines were mentioned (WHO, 2015).
Concluding the World Health Assembly (WHA) 67.20
Resolution, the recommendations to Members State,
WHO and other stakeholders were in favour of the fulfilment of the 2005 Strategic Plan. Some of the recommendations included:
•

assessment of regulatory capacity of the NMRAs
using WHO benchmarking tools;

•

collaboration of the national NMRAs to form regional blocs that will move towards regulatory
convergence and transparency in decision-making;

•

development of strong legal basis and political direction to support regulatory systems;

•

pooling together of resources, regulatory experts,
adopting/adapting already developed technical
guidelines and guidance;

•

strengthening of regulatory system as a component of expansion of local and regional production
of quality, safe and efficacious medicines (WHO,
2015).

2018 Report of IGAD – Inter-Governmental Authority on Development
The Inter-Governmental Authority on Development
(IGAD) is one of the Regional Economic Blocs (REC)
in Africa, situated in the horn of Africa comprising
Djibouti, Ethiopia, Eritrea, Kenya, Somalia, Sudan,
South Sudan and Uganda (Adan & Toroitich, 2018).
With respect to the Strategic Plan of the AMRAC in
2005, IGAD seems to have made progress in some
areas of medicines regulation, but due to challenges
highlighted by Adan and Toroitich (2018), there is still
much to be done. Some achievements that were mentioned include but not limited to:

•

IGAD Member States working together to establish regional cross-border health policies and sector specific strategies on RMNCHN, MRH, TB and
HIV;

•

MRH Workplan for 2019,

•

established Technical Working Groups on Medicines, Pharmacovigilance and Information Management System (IMS),

•

prepared draft technical documents on IGAD dossier submission,

•

IGAD Marketing Authorization, procedure of Joint
Assessment of medicines dossier in IGAD’s region and Quality Guidelines.

From the report of Adan and Toroitich (2018), as in
other RECs in Africa, the level of medicines regulation
in IGAD seemed to be characterized with varied regulatory capacity in the Member States, where medicines regulation was still domiciled in a department
under the Ministry of Health (non-autonomous
NMRAs). WHO Collaborative Registration Procedure
(CRP) was functional in some countries in the region.
Junior assessors were trained on medicines dossier
assessment. According to Adan and Toroitich (2018),
IGAD was not able to implement their MRH activities
due to challenges which included inadequate technical and human resources funds. Adan and Toroitich
(2018) solicited for equal strengthening and handling
of the RECs in Africa in order to fulfill the vision of the
AMRH program and AMA.
Industry Perspective of East African Community
(EAC) MRH in 2019
After 2005, the SSA countries started earnestly implementing the recommendations from the AMRAC and,
by 2009, the African Medicines Regulatory Harmonization (AMRH) agreed to develop regional platforms
with harmonized regulatory procedures for the registration of medicines. EAC region started first in 2012
and six years later, by 2018, a study by Storehagen et
al. (2019) was conducted to evaluate the industrial
perceptions of medicines regulatory harmonization in
the East African Community (EAC).
The pharmaceutical industry, though favourably disposed to the medicines regulatory harmonization, still
had their reservations regarding the harmonization initiative because of the length of time it took to receive
the actual marketing authorization. The challenges included getting all EAC countries to recognize EAC approvals, unexpectedly higher quality standards compared to national procedures, smaller, less attractive
markets not appealing from a corporate perspective
and the absence of free trade of pharmaceuticals in
the EAC region despite the existing EAC Free Trade
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Agreement, which officially launched the free movement of goods and services in 2010.
The Storehagen study was a semi-structured interview with document reviews. The main target group
for the interviews was pharmaceutical companies
(18 companies, including 64% of the total companies
who had experienced the EAC joint product assessment procedure, and two EAC-based national medicines regulatory authorities). Although harmonization
had been thought to be one of the solutions to modern regulation, the study showed that harmonization
must be handled appropriately with all factors correctly mixed before success can be achieved. The
method used in the study was effectively able to assess the EAC harmonization. Results showed that
improvements were required in order for the current
EAC processes to meet the vision of harmonization.
Harmonization will result in quicker access to the
harmonized markets for quality-assured medicines
(Storehagen et al., 2019).

WHO Regulatory Support
The World Health Organization (WHO) offers support
with respect to medicines regulation using three approaches:
•

development of international norms, standards and guidelines;

•

offering of guidance and technical assistance;

•

training and collaboration with NMRAs, development organizations, and other UN agencies.

Specifically, WHO assesses the NMRAs, provides
guidelines, guidance and manuals, provides training
opportunities on model computerized registration system (SIAMED), model web-site, WHO prequalification
of medicines moving in international commerce, international cooperation and harmonization and during
International Conference of Drug Regulatory Authorities
(World
Health
Organization,
2019).
WHO recognizes the sovereignty of countries’
NMRAs to regulate and control. According to WHO
(2019), expectation of NMRAs structure and functions:
Solid legal basis, realistic objectives, appropriate organizational structure, adequate
number of qualified staff, sustainable financing, access to up-to-date evidence based
technical literature, equipment and information, capacity to exert effective market
control. MRAs must be accountable to both

the government and the public and their decision-making processes should be transparent. Monitoring and evaluation mechanisms
should be built into the regulatory system to
assess attainment of established objectives
(p. 1).
All of the regulatory support provided by WHO is to
ensure effective regulation. Effective regulation involves the following among others: ensuring quality,
safety and efficacy of medicines, good manufacturing
practice, distribution, storage of medicines, ensuring
rational use of medicines by patients and prescribers,
enforcement, detection of illegal manufacturing, adequate sanction, fair promotion and advertisement that
is geared towards allowing rational use of medicines
and observing Good Regulatory Practice (World
Health Organization, 2019).
EAC-MRH
The East Africa Community Medicines Regulatory
Harmonization (EAC-MRH) Project is the first regional
bloc MRH of the African Medicines Regulatory Harmonization Program and Global Medicines Regulatory Harmonization Initiative sponsored by technical
and financial partners – AUDA-NEPAD, WHO, World
Bank and the BMGF (BCG, 2017). The EAC Secretariat, together with the NMRAs of the Partner State
of EAC, took this initiative in order to ensure availability of quality, safe and efficacious medicines.
Some of the successes recorded at the end of five
years of EAC MRH Project were the development of
harmonized requirements – guidelines, guidance,
manuals and SOPs. The Joint Assessment procedure
approved nine medicines out of 45 applications that
were filed. The median months for obtaining Marketing Authorization was reduced to eight months from
14. Some of the things that were not achieved within
the five years included harmonization of the IMS,
meeting of the procedure timelines for the Joint Assessment and Good Manufacturing Practice (GMP)
(BCG, 2017). After its assessment, the EAC MRH received recommendations for another five years
(2018-2022), in which in short term, it would be required to continue the MRH for another 6 months, medium term, prove the sustainability and value addition
of the MRH for 18 months and in the long term, establish a semi-autonomous East Africa Healthcare Products Agency – EAHCPA and mutual agreement
among the NMRAs before the end of 36 months
(BCG, 2017).
SADC – ZAZIBONA
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The ZaZiBoNa, meaning Zambia, Zimbabwe, Botswana and Namibia, in the Southern African Development Community (SADC) region was initiated in 2013
to jointly assess medicine dossiers submitted in these
countries. The ZaZiBoNa approach reduced the median timeline from dossier submissions to national
Marketing Authorization to eight months, through Collaborative Registration Procedure (CRP) (NdomondoSigonda et al., 2017). At its 12th Session reported in
the NEPAD newsletter, six out of 13 dossiers assessed were recommended for approval (NEPAD,
2016).
ECOWAS
The Economic Community of West African States
(ECOWAS) is the regional body of the fifteen countries in West Africa (Benin, Burkina Faso, Cabo
Verde, Cote d’Ivoire, Ghana, Guinea, Guinea Bissau,
Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone,
the Gambia and Togo) (ECOWAS, n.d.) to promote
economic integration. It was established on May 25,
1978 by a treaty, termed – Lagos Treaty (ECOWAS,
n.d.). The integrated economic activities, as envisaged, revolved around, but were not limited to industry, transport, telecommunications, energy, agriculture, natural resources, commerce, monetary and financial issues, and social as well as cultural matters
(ECOWAS, n.d.). Among the specialized Agencies of
ECOWAS was the West African Health Organization
(WAHO).
WAHO
WAHO was created by the Protocol A/P2/7/87 on July
9, 1987 and signed in Abuja, Nigeria by the Heads of
State and government to ensure coordination of regional health interventions within the ECOWAS region
(WAHO, n.d.-a, n.d.-b; West African Health Organization, n.d.). Aligning with the desire of the ECOWAS
Government to move from being a ‘Community of
State’ to a ‘Community of the People’ by 2020, WAHO
made every effort to produce high impact and costeffective health interventions that would be felt by
members of ECOWAS community and international
community as proactive regional health integration instrument ([WAHO, n.d.). According to West African
Health Organization, the new Thematic Areas that
they were focusing on in the time of recurring epidemics and scarcity of resources included:
1. maternal, child & adolescent health quality
standards & centres of excellence
2. pharmaceuticals (medicines & vaccines)
3. prevention & control of communicable and
non-communicable diseases)

4. health Information
WAHO also ensured capacity building, youth development, strengthened networks and sustainability
during the implementation of any of the thematic areas
(WAHO,
n.d.).
The big picture of pharmaceuticals (medicines, vaccines and other health products), their manufacture,
regulation and key related activities for 2014-2019
were described in the ECOWAS Regional Pharmaceutical Plan (ERPP). This was the consolidated approach (Ossei-Yeboah-Agyeman, 2017) that had
been accepted by the international community, Assembly of Health Ministers, Heads of State and Government of ECOWAS Member State (Ossei-YeboahAgyeman, 2017).
ECOWAS Regional Pharmaceutical Plan ERPP
2016-2020
The ERPP (ECOWAS, 2014) had eight objectives
(Ossei-Yeboah-Agyeman, 2017), which were the following:
i.

strengthen the National Medicines Regulatory Authorities (NMRAs) regulatory capacity
and quality infrastructure in the ECOWAS region to achieve International Certification and
designation as Regional Centers of Excellence by the year 2018;

ii.

strengthen local production of pharmaceuticals in the region;

iii.

improve and strengthen the governance of
the pharmaceutical systems;

iv.

promote and support competitive and efficient
regional pharmaceutical manufacturing to ensure the supply of essential medicines produced in the region; support provision to
pharmaceutical manufacturing in order to
achieve international certification;

v.

reduce incidence of Substandard and Falsified (SF) medical products in the ECOWAS
region by 75%;

vi.

establish of a regional medicines regulatory
Agency;

vii.

facilitate of the incorporation of ECOWAS policies on TRIPs flexibilities into national laws;

viii. formulation and implementation of policies
that will promote innovation, research and development into pharmaceuticals and medicinal products within the ECOWAS region as
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well as establish a competitive grant in the
ECOWAS region (WAHO, 2014).
NMRAs in ECOWAS
There were National Medicines Regulatory Authorities (NMRAs) in each of the 15 Member States of
ECOWAS. They were, however, different in functionality and system due to their economic and political
heritages. Prior to coming together under the West African Medicines Regulatory Harmonization initiative,
the eight French countries had regulatory systems
similar to that of France, the five English countries had
a different system to that and two Portuguese speaking countries had a different system. These were all
at different levels of development in terms of autonomy, governance, system and structure.
However, in 2014, with the support of the technical
and financial partners such as the New Partnership
for Africa’s Development (NEPAD), World Health Organization, World Bank, Bill and Melinda Gates Foundation, the two main regional bodies in West Africa
(Union Economie Monetaire Ouest African [UEMOA]
and West African Health Organization under the leadership of the ECOWAS), came together to integrate
their medicines regulation harmonization systems and
made it more efficient because they agreed to establish the West African Medicines Regulatory Harmonization (WA-MRH) Project. Also established were a
Steering Committee comprising the heads of the 15
NMRAs, to provide direction and the Experts Working
Groups which were to provide technical assistance
and help develop technical documents in the seven
major regulatory domains (Ossei-Yeboah-Agyeman,
2017; World Bank, 2012).
Regulatory Functions of the NMRAs in ECOWAS
from data obtained from 2005, 2010 and 2017 reports
i.

Authority and Legal Forms of the NMRAs

Ndomodo-Sigonda et al. (2017) reported 53 out of 54
countries in the sub-Saharan Africa had NMRAs or
administrative entities that carried out some form of
regulatory functions. Some were semi-autonomous,
meaning they have some levels of independence from
the Ministry of Health (MoH) in carrying out their regulatory functions; while others are Departments in the
Ministries of Health. The mandate of some NMRAs
covered medicines, food, medical devices or cosmetics, while others were medicines and medical devices
only. The funding of the NMRAs varied – some were
fully funded by the government and therefore, required to remit all revenue generated to the single
government treasury; others were permitted by the
government to retain some percentage of revenue

generated for day-to-day running of the organization
(Ndomondo-Sigonda et al., 2017).
In most of those NMRAs that were departments in the
Ministry of Health, the core regulatory functions expected of an NMRA were usually carried out by different departments in or out of the Ministry of Health. In
West Africa, there were examples of the semi-autonomous and non-autonomous NMRAs, with core regulatory functions being carried out by several departments of the Ministry of Health. However, throughout
the years, there was greater awareness among the
government of ECOWAS Members State to grant autonomy or semi-autonomous status to their NMRAs
and the increasing number of NMRAs were gradually
moving towards becoming an Agency (WAHO, 2018).
ii.

Marketing Authorization

The process of registration of medicines (Marketing
Authorization) was considered one of the core regulatory functions of NMRAs (Ndomondo-Sigonda et al.,
2017; WHO, 2010). WHO’s report presented the results of the assessments of regulatory systems of 26
sub-Saharan African countries (24 belonging to the
WHO AFRO region of which eight NMRAs were of the
West Africa region, six French speaking and two were
English speaking) over the last eight years, to identify
regulatory gaps and suggest priority activities to
strengthen regulatory capacity (WHO, 2010). The report recognized that NMRAs must meet six major requirements in order to be able to assess applications
for marketing authorization. They are:
i.

legal basis, giving the NMRA the power to
grant, renew, vary, suspend and withdraw of
marketing authorization;

ii.

guidelines for applicants regarding the details
of technical requirements for medicines dossier to be assessed;

iii.

standardized operating procedures to assess
submission, communicate and publish outcomes;

iv.

adequate expert assessors;

v.

secure storage, retrieval and exchange of
data with other regulatory departments;

vi.

Mechanisms to consider the decisions of
stringent NMRAs (WHO, 2010).

The scenario in West Africa gradually started to resemble the proposed structure by the WHO, especially with the support of technical and financial partners who sponsored the West African Medicines Harmonization Project. The project was officially
launched in November 2017 and contributed to the
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development of both regional and national capacities
in the domain of medicines dossier evaluation and
registration (WA-MRH-WAHO, 2017).
iii.

Good Manufacturing Practice (GMP)

Good Manufacturing Practice inspection is conducted
in pharmaceutical facilities to ensure that manufacturing activities carried out in such facilities were according to recognized international standards (WHO,
2010). The WHO’s report of 2010 demonstrated a
system to carry out inspections existed in most
NMRAs that were assessed. However, this activity
was not carried out by the NMRAs in some countries.
Sometimes the inspection was done in conjunction
with another government institution (WHO, 2010).
All member states in West Africa participated in the
WA-MRH Project. The Experts Working Group on
GMP established in the WA-MRH Project, developed
guidelines, guidance and SOPs in accordance to
WHO international GMP Guidelines. There was ongoing joint inspection, which included training among the
experts and other Members State. The EAC-MRH has
a similar group as the WA-MRH which developed harmonized guidelines on GMP inspection (NdomondoSigonda et al., 2017).
The West African Health Organization (WAHO) working with the United Nations Industrial Development
Organization (UNIDO), assessed manufacturing facilities and trained both NMRAs inspectors and manufacturers in Members State of ECOWAS. GMP
roadmaps were developed for the region and nations
with or without manufacturing sites. They also developed Corrective Action and Preventive Action (CAPA)
for all manufacturers that were assessed (Ekeigwe,
2019).
iv.

Quality

Control

of

Medicines

The United States Pharmacopoeia (USP) worked in
collaboration with AUDA-NEPAD, WAHO and other
Regional blocs to establish the Network of Official
Medicines Control Laboratories (NOMCOL) for laboratories within Africa and its regional blocs. WAHO, in
conjunction with USP, carried out an assessment of
the laboratories in West Africa and proposed recommendations that would strengthen the capacity of the
laboratories in the region with respect to purchase
and maintenance of laboratory equipment, training of
human resource and purchase of reference standards
to help with testing.

v.

Quality Management Systems (QMS)

The WHO report of the rapid assessment of 26
NMRAs in sub-Saharan Africa revealed that as of
2010, none of the NMRAs had established a robust
and comprehensive Quality Management System to
support their regulatory functions (WHO, 2010).
According to the 2017 report of Ndomodo-Sigonda et
al., the East African Community Medicines Regulatory, harmonization was able to develop harmonized
guidelines on Quality Management System (QMS).
The QMS of NMRAs in West Africa were assessed
between 2015 and 2017 and, based on observed
gaps, developed the roadmaps to be followed by each
Member State to arrive at attaining ISO 9001:2015
and Pharmaceutical Inspection Cooperation Scheme
(PICS) (Ossei-Yeboah-Agyeman, 2018; WAHO,
2018).

vi.

Information Management System

The Information Management Systems (IMS) in the
NMRAs in West Africa were upgraded since the WAMRH Project. Harmonized guidelines and SOPs were
developed. A handful of NMRAs in the West African
region had functional websites where regulatory information such as registration status of medicines, licensed manufacturing sites and information were
shared with relevant stakeholders. The development
of some of these websites were sponsored by the
WA-MRH project.
vii.

Harmonization and International Cooperation

All NMRAs in West Africa were participating in the
West Africa Medicines Regulatory Harmonization
Project (WA-MRH), which is discussed below:
WA-MRH Project
The West African Medicines Regulatory Harmonization Project (WA-MRH) launched in November 2017
with the aim to ensure availability of quality medicines through harmonization of regulatory systems
that will be effective and transparent. The WA-MRH
Project had an initial focus on four domains of medicines regulation, namely: medicines evaluation and
registration, Good Manufacturing Practice (GMP) Inspection, Quality Management System (QMS) and
Information Management System (IMS). These focus
areas were sponsored in the past, for two years, by
the technical and financial partners of the umbrella
program and initiative – AMRH and GMRHI (WHO,
AUDA-NEPAD, World Bank, Bill and Melinda Gates
Foundation, Swissmedic).
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Table 1 Summary of timelines, occurrences accomplishments of each time period stated above and their significance.
Occurrences / details of
Accomplishments of each
Significance
each time period
time period
Early History
the history of the foundation
Beginning of medicines regulation.
a. Beginning of Regulatory
of modern medicines regulaInspections and Enforcetion
ment in London.
Helped establish the standard Standard formulations of medicines
b. The Beginning of the
formulations of medicines and became possible, several manufacPharmacopoeia in Florthereby lifted the limit of the
turers for one medicines became
ence, Europe.
manufacturers of medicines.
possible and regulatory inspection
was established.
1540-1865

Further Development to Medicines Regulation in Europe

Modern

a. United States Food and
Drug Administration
(USFDA) 1930-1938.

b. 1975 – Commencement
of Harmonization in Europe

c. 2003 – The Establishment
of the UK Medicines and
Healthcare Products Regulatory Agency (MHRA)

d. 2005 - Medicines Regulation in Africa

The accelerated evolution of
regulation of medicines in Europe.
The formation of the Food
and Drug Administration from
Bureau of Chemistry in the
Department of Agriculture;
The creation of new provisions in federal Food, Drug
and Cosmetic (FD&C) Act for
manufacturers to demonstrate
that a drug was safe before it
could be marketed.
The idea of harmonization
was introduced. The Mutual
Recognition Procedure began
and the Central Procedure to
ensure a common market for
medicines in Europe;
Collaboration started among
Japan, the European Union
and the United States of
America to yield International
Conference on Harmonization
of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH)
where dossiers of new and innovative medicines would be
evaluated to ensure quick access to the people who
needed them most.
Establishment of the Medicines and Healthcare Products Regulatory Agency
(MHRA) in the United Kingdom (UK).
Documentation of the
strengths, weaknesses, opportunities and recommendations of medicines regulation
in Africa and development of
a five-year strategic plan for
improvement.

Commencement of medicines regulation in Europe.
Commencement of medicines regulation in the United States of America.

The commencement of the Common Technical Document (CTD)
used in the International Conference
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

The UK joined the League of Nations - USA and in Europe, where
both medicines and medical devices
are housed under one organization.
Setting of the first set of strategies
and roadmap for development of
medicines regulation in Africa.
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e. 2014, World Health Assembly 67.20

Assessment of regulatory capacity of the NMRAs using
WHO Global Benchmarking
Tools (WHO-GBT);
Collaboration of the national
NMRAs to form regional blocs
that will move towards collaboration, regulatory convergence , and transparency in
decision-making;

A call of the WHO to Regulatory
System Strengthening for medical
products.
Highlighted the pivotal role of the
World Health Organization to support of the establishment and sustainability of an effective regulatory
system in developing countries.

Development of strong legal
basis and political direction to
support the regulatory systems;

f.

ECOWAS Regional Pharmaceutical Plan ERPP
2016-2020.

Pooling together of resources,
regulatory experts, not re-inventing the wheels but adopting / adapting already developed technical guidelines and
guidance;
Strengthening of regulatory
system as a component of expansion of local and regional
production of quality, safe and
efficacious medicines (WHO,
2015).
The consolidated approach
for development of medicines
regulation in the West Africa
accepted by the ECOWAS
Assembly of Health Ministers,
Heads of State and Government and international community.
ix. Strengthen NMRAs regulatory capacity and
quality infrastructure in
the ECOWAS region to
achieve International
Certification and designation as Regional Centers of Excellence;
x.
strengthen local production of pharmaceuticals
in the region;
xi. improve and strengthen
the governance of the
pharmaceutical systems;
xii. promote and support
competitive and efficient
regional pharmaceutical
manufacturing to ensure
the supply of essential
medicines produced in
the region;

The involvement of 15 Members
States in West African Medicines
Regulatory Harmonization (WAMRH) Project with the support to
with the support of technical and financial partners;
The ECOWAS harmonized Common Technical Document (CTD);
Etc.
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xiii. reduce incidence of Substandard and Falsified
(SF) medical products in
the ECOWAS region by
75%;
xiv. establish of a regional
medicines regulatory
Agency;
xv. facilitate the incorporation of ECOWAS policies
on TRIPs flexibilities into
national laws;
xvi. Formulation and implementation of policies that
will promote innovation,
research and development of pharmaceuticals
and medicinal products
within the ECOWAS region as well as establish
a competitive grant in
the ECOWAS region.
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Justification
The literature revealed that there was a scarcity of information on human resources in the arena of medicines regulation in sub-Saharan Africa (SSA)
(Ndomondo-Sigonda et al., 2017). This scarcity of information was also found in all the domains of medicines
regulation
in
sub-Saharan
Africa.
The information on medicines regulation were not
easily found. The published information on medicines
regulation in ECOWAS region was no longer current.
Additionally, the available information was no longer
consistent with the current realities in the NMRAs.
Much has changed, but the published information on
medicines regulation in Africa are still those that were
presented in 2005, 2010 and 2017. There was also a
need to know the trend, how the region fared since
the 2005 meeting of the heads of African medicines
regulatory
authorities.

Objective
This research paper had three main objectives:
1.
It aimed to put together a story of
medicines regulation in Africa.
2.
It compared the data found in 2005,
2010 and 2017 research papers and reports
and attempted to discover any trend (increasing or decreasing) in the state of medicines
regulation in West Africa.
3.
The results of the comparison revealed the existence of any gaps, proposed
solution(s) or available opportunities that
were within and outside the region to address
those gaps.

2. METHODS
Documentation review
A literature map was prepared to provide the framework and scope that guided the search and review of
relevant literature.
The search of the literature was carried out according
to the literature map, which is in a hierarchical structure, from top to bottom, using the dates, starting at
the earliest time when events occurred in medicines
regulation to the latest time, leading to the bottom with

the proposed study. The selected literature was summarized, building bridges between related topics in
Medicines Regulation and identifying central issues of
previous scholarly work written on medicines regulation across the globe, in Africa and more specifically,
West Africa.
Choice of Reference Research Paper and Report
During the literature search and review, some reports
and research papers stood out because they had information on the assessment that was done on medicines regulatory systems and structure in sub-Saharan Africa and their outcomes at specific times in
the past. There was one 2005 report of the First African Medicines Regulatory Authorities Conference,
which had information on the state of the regulatory
systems and structure in Africa as of 2005, which proposed a strategic plan (2006-2010) with recommendations and next steps going forward. This, then, became a reference to measure subsequent medicines
regulatory plans and activities in the continent.
Another important document that was used was the
report of the rapid assessment of 26 NMRAs in subSaharan Africa that was carried out by the World
Health Organization (WHO) between 2006-2010. This
became another point of reference to compare what
was found in 2005 to what WHO reported in their 2010
published report.
A third report, a paper by Ndomondo-Sigonda et al.
(2017) compiled the state of medicines regulation in
all the NMRAs in the sub-Saharan Africa as of 2016.
This report described the trend of medicines regulation since 2005, when the regulatory authorities first
met.
The following systems and structure of medicine regulation were the focus of the comparison: authority
and legal forms of the NMRAs, existence of Marketing
Authorization, conduct of Good Manufacturing Practice inspection, harmonization and international cooperation, existence of Quality Management System, Information Management System and Quality Control
Laboratory(s). These seven areas were chosen as the
focus because their existence in a medicines regulatory system gave an idea of the maturity of the NMRA.
During the courses of this study, several other reports
and papers were consulted in order to obtain specific
information on these seven focus areas; some of
which were the reports of countries under the WAMRH Project, Project Papers of World Bank funded
Projects, reports of WA-MRH and SWEDD Projects
and reports of other activities as were deemed fit. Certain information on Quality Management Systems of
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the NMRAs were obtained from reports of assessments and surveys.
Choice of Countries and Collation of Data in the
Research
The countries that were chosen for a closer look from
the 2005, 2010 and 2017 reports were the fifteen
Members States of ECOWAS. The data obtained
from the Strategic Plan 2006-2010 were mined from
the report of the First African Medicines Regulatory
Conference and were regarded as the 2005 data. The
data from the report of the assessment of regulatory
systems of twenty-six countries that the WHO assessed were mined from the report and were taken as
the 2010 data. The data on medicines regulatory report of Ndomondo-Sigonda (2017) were mined and
used as the 2017 data. The data that were obtained
from the 2005 Strategic Plan were used as the baseline to compare the data obtained from the reports of
2010 and 2017.

also concluded on how the NMRAs have matured according to pre-determined expectations. In future
work, this study with its methodology could be used to
understudy the remaining core regulatory areas in the
NMRAs to allow for discovery and filling of existing
gaps.

3. RESULTS AND DISCUSSION
The results obtained from the comparisons of 2005,
2010 and 2017 data revealed the following major
points:
•

None of the papers had information on all the
Members State of ECOWAS as demonstrated by
Tables 1, A3-A9.

•

The three papers used for comparison did not
measure the same parameter/indicators. One paper measured some set of indicators and left out
one or more, while the other papers measured
other indicators, hence empty spaces in Tables 39.

•

Information on core regulatory features that was
not provided in the paper was unavailable on the
websites of NMRAs, various reports, national
government websites, WHO websites and African
Union website.

•

Another reason why some of the Members States
in ECOWAS were omitted or not measured could
have been due to the sampling size per regional
blocs and/or inclusion – exclusion criteria.

•

The comparison of the data obtained in 2005,
2010 and 2017 showed an increasing trend in the
number of NMRAS that became autonomous
over the years – 2005 (6.67%); 2010 (13.33%)
and 2017 (26.67%). This demonstrated that the
governments of countries in ECOWAS were becoming more aware of the need to grant some
form of independence to their NMRAs in order to
have unhindered/unrestricted judgement of medicines with respect to quality, safety and efficacy.

•

Concerning Marketing Authorization, the 2010
and 2017 reports had varying information. There
are some countries that the 2010 report said they
have NMRAs that grant Marketing Authorization
(MA), which the 2017 report said were unavailable.

•

This led to the fluctuating trend that is observed
by the following percentage when the 2005, 2010
and 2017 were compared – 2005 (6.67%), 2010
(53.33%) and 2017 (33.33%).

Analysis of the report obtained
The data obtained from the 2005, 2010 and 2017 reports were anayzed. In order to quantify the information obtained from the reports, all responses that
had a “Yes” or positive inclinations were assigned “1,”
while the “No” or negative inclination responses were
awarded a “0.” In any situation where a response was
“Yes/No,” “0.5” was assigned. The countries in which
the reports had no information on the regulatory feature were assigned nothing.
The sum of these numbers obtained by the 15 countries per regulatory feature were taken and percentages calculated. The information from the 2005 report
was used as the reference for this study. 6.67% derived from one over fifteen was assigned as the least
percentage of the chosen regulatory features for all
the 15 ECOWAS countries. A zero (0) could not be
assigned to that year even though, the report did not
have information on specific countries’ NMRAs, it was
the year that the regulatory problems were identified,
captured in a report and solutions were proposed in
form of a strategic plan.
Advantages of the research work
This study highlights the trends that are in medicines
regulatory systems of the 15 NMRAs in ECOWAS region from the data gathered from 2005, 2010 and
2017. The trend that was revealed by this study will
demonstrate to stakeholders (manufacturers, donor
partners, researchers, policy makers, WAHO management) whether medicines regulated by the
NMRAs in the region were progressing. This research
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of NMRAs with QMS, 2005 (6.67%); 2010 (10%)
and 2017 (26.67%) despite that the report of 2017
had “unavailable” as information for most of the
NMRAs.

•

The variation observed in the information derived
from the countries and NMRAs’ data may have
resulted from the difference in the methodology
used to derive the 2005 and 2010 data.

•

The 2010 report explained that countries were
visited in order to obtain or confirm the information, while the methodology used in the 2017
was a search of information on the NMRAs’ and
countries’ websites and reports.

•

Information Management System (IMS) was a
regulatory feature not captured in the 2017 report,
but was captured by 2010 report. There is an increasing trend (Appendix VII) observed – 2005
(6.67%) and 2010 (20%).

•

Regarding conduct of Good Manufacturing Practice (GMP) by the NMRAs or another body/institution in the countries, there was an increasing
trend in the number of NMRAs conducting GMP
inspection, 2005 (6.67%), 2010 (20%) and 2017
(40%).

•

•

The 2010 report specified that regulatory inspection was being done in some countries, by another entirely different government institution; or
the responsibility for regulatory inspection was
shared with such institution.

The aspect of Harmonization and International
Cooperation was not reported in one of the reports (2010). However, a steep increase was observed between the two reports that reported this
regulatory feature. There was an increase in the
number of countries/NMRAs involved in harmonization and international cooperation over the
years – 2005 (6.67%) and 2017 (86.67%).

•

Overall, from the results obtained by comparing
the data from the 2005, 2010 and 2017 reports, it
can be said that there was increase in the number
of the NMRAs that have progressed in the seven
regulatory features that were measured in this paper.

•

Literature showed the beginning of medicines
regulation as early as 200 BC – 100 AD. The beginning of the UK’s Medicines and Healthcare
Products Regulatory Agency (MHRA) in 2003
was found and the report of the First African Medicines Regulatory Conference that took place in
Addis Ababa in 2005, where the Mother-Plan (a
Strategic Plan 2005-2010) for Medicines Regulation in Africa was formed was discovered.

•

The 2017 report did not specify whether the regulatory GMP inspection was done solely by the
NMRAs or was shared with other governmental
institutions.

•

The comparison of the 2005, 2007 and 2010 reports, regarding Quality Control of Medicines,
showed an increasing trend in the number of
countries that were testing medicines for declaration of quality – 2005 (6.67%); 2010 (20%) and
2017 (53.33%).

•

The Quality Management System (QMS) showed
an increasing trend (Appendix VI) in the number

18
Table 2 Summary of Regulatory Features of the MRAs in ECOWAS derived from the 2005, 2017 and 2019 Reports.
S/No

Some Features of a Medicines Regulatory Authority

2005

2010

2017

Authority and Legal Form of the NMRAs

6.67

13.33

26.67

Marketing Authorization

6.67

53.33

33.33

Good Manufacturing practice Inspection

6.67

20

40

Quality Control Laboratories

6.67

20

53.33

Quality Management System

6.67

10

26.67

Information Management System

6.67

20

-

Harmonization and International Cooperation

6.67

-

86.67

Summary of Regulatory Features of the
MRAs in ECOWAS derived from the 2005,
2017 and 2019 Reports

7. Harmonization…
6. Information…
5. Quality…
4. Quality Control…

-

I

I

I

I
I

Future Study

3. Good…
2. Marketing…

I

1. Authority and… I
I

0.

25.
2005
■

medicines policies, regulation and legislation, establishment of Regulatory Centres of Excellence
(RCOREs), were all recommended activities from the
2005 Mother Plan made by the Heads of the NMRAs
and stakeholders. The contributions of various stakeholders of medicines regulation such as WHO, Stringent Regulatory Authorities (SRAs) were in tandem
with the Mother-Plan over the years.

50.
2010
■

75. 100.
■ 2017

Figure 1 Percentage information captured on some core
regulatory features of the NMRAs in ECOWAS in the
2005, 2010, 2017 Reports.

The literature post-2005 regarding the regulation of
medicines in Africa, the Regional Economic Blocs revealed that the ongoing, vibrant activities on regulatory harmonization in the RECs, development of the
African Union Model Law, development of in-country

Future study would consider 2019 data on medicines
regulation in Africa/West Africa and compare it with
the results of 2005, 2010 and 2017 to trend progress
and determine if any had been made. The 2019 data
that would be collected would served as baseline
data, which would be used to start the assessment of
the other core regulatory functions carried out by the
NMRAs in ECOWAS going forward.
A copy of the proposed questionnaire is in Appendix
1 of this paper.
Another future focus of this study would to carry out
qualitative study which will allow to go into the details
of these identified systems and structures in order to
measure their strength and quality.
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4. CONCLUSION
In conclusion, the comparison of the 2005, 2010 and
2017 reports showed that there was missing information on the regulatory features of countries that
were studied. The indicators measured in the different
reports compared, were, in some cases, not the
same, maybe due to the differences in objective of
studies, exclusion and inclusion criteria which are peculiar to studies and the methodology used. Overall,
the comparison of the report revealed that there was
cumulative progress in the regulatory features measured in Members State of ECOWAS over the years
2005 through 2017.

governments of ECOWAS Members State for securing adequate authority and autonomous legal
status for the NMRAs in the West Africa region.
•

Continue to advocate that all regulatory functions
are carried out by only the NMRAs. For example,
the Good Manufacturing Practice inspections are
carried out solely by the NMRAs of the countries
and not shared among governmental institutions.

•

With respect to the Quality Control laboratories,
WAHO and the AUDA-NEPAD should keep up
the advocacies to government of countries to finance their National Medicines Control Laboratories (NMQCLs). These NMQCLs are faced with
numerous challenges ranging from inadequate
equipment, maintenance of them, reference
agents and qualitative and quantitative human resources. WAHO, USP and WHO are working in
collaboration directly with the NMQCLs to ensure
that these needs are met (Ekeigwe, 2019;
WAHO-USP, 2019).

•

All the NMRAs in ECOWAS are actually participating the West African Medicines Regulatory
Harmonization (WA-MRH) Project and have benefited with respect to strengthening capacities in
Dossier evaluation, GMP inspection, QMS, IMS
(WAHO, 2020; World Bank, 2012).

•

The NMRAs are further encouraged to continue
to explore the opportunities available in the regional and continental medicines regulatory initiatives (AMRH and WA-MRH) with regards to Information Management System and Harmonization / international cooperation.

The essence of the finding of the study is that Africa
and its regional blocs’, especially West Africa’s, medicines regulatory landscape changed. The development of Medicines Regulation has made significant
progress. The contributions to improvement in the
West Africa region have been gradual but sure.

5. RECOMMENDATIONS FOR NEXT
STEPS (OPPORTUNITIES)
The recommendations and next steps that are specific to this research follows:
• Keep updating unifying regional and national indicators on which the Monitoring and Evaluation Officers at the regional and national levels should be
trained and re-trained. The Africa Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD), RECs with the collaboration of WHO, unified the indicators that are
now being measured in the regional blocs. The
training of West African regional and national
Monitoring and Evaluation (M&E) officers on the
uniformed AMRH M&E Data Collection Tool
(AUDA-NEPAD, 2019b) was conducted in Abidjan, Cote d’Ivoire in 2019 (AUDA-NEPAD,
2019a). The process of development of uniform
indicators was completed in 2017, piloted in 2018
in the regional blocs with accompanying training
and collection of data in 2019.
•

Ensure that each of the NMRAs in West Africa
has functional and robust Information Management System (IMS) exemplified by a functional
website linked to the government websites. Further, ensure that the regulatory information and
the vital signs of regulatory authorities are obvious and available to interested stakeholders.

•

The regional, continental institutions, technical
and financial development partners (WAHO,
AUDA-NEPAD, WHO, World Bank, BMGF)
should ensure continued advocacies towards the

This recommendations from this research encouraged all stakeholders to take steps towards complete
implementation of the interventions proposed in the
2005 Mother plan and subsequent continental and regional plans. The recommendations also encourage
Competent Authorities, responsible bodies, organizations and institutions to cooperate and collaborate,
specifically to review the Mother plan, and propose
another Strategic Plan (5-10 year) for medicines regulation in Africa.
•

The regional and national regulatory authorities
should make use of available opportunities in the
continent and region to strengthen their regulatory
capacities. Some of which are the opportunities
available in the proposed Africa Medicines
Agency, Africa Medicines Regulatory Harmonization (AMRH) and the regional harmonization initiatives. Others include harmonized guidelines,
guidance and procedures for the Joint Assessment (JA) of medicines dossiers procedure, joint
inspections, Quality Management System which
provide minimum acceptable standards. There is
also the Information Management System for
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sharing and exchanging of information among
Members State (Ndomondo-Sigonda et al.,
2017).
Additional opportunities that should be seized are the
pool of regional/continental experts, the Regional
Centre of Regulatory Excellence (RCOREs) that ensure sustainable training in the regions/continent, Network of Medicines Control Laboratories (NOMCOLs),
the alignment of Africa Vaccines Regulatory Forum
(AVAREF) with AMRH, WHO Collaborative Registration Procedure.
The results of this work demonstrate value for similar
reviews by other regional blocs to demonstrate the
progress that their regions have made with respect to
the Strategic Plan of 2005, WHO assessment report
of 2010 and other published literature. Members State
in ECOWAS that are still lagging behind in one regulatory function, structure and system should continue
to make efforts, whether with advocacies with their
governments through the specialized regional body
on health (WAHO) or building of capacities using opportunities of their governments’ subventions in order
to ensure sustainability or provisions made by regional, continental and international initiatives. There
will be a need to establish a list of the expectations for
the coming years or to develop another plan for medicines regulation in Africa, teased from African Union
Agenda 2063 or other continental, plan that will be
monitored and evaluated to demonstrate progress
made.
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Proposed questionnaire for review towards the 2019-2020 survey
Table A2 A sample of one of the proposed Questionnaires to gather information on the systems and structure for granting
Marketing Authorization in the NMRAs in ECOWAS.

Questionnaire
Name of NMRA:
Country:
Date:
Information on the System of Registration of Medicines in NMRA in ECOWAS

Data Collection (2019)
S/NO

Data Collection Requirements (What needs to be measured?)

Is NMRA using the Common Technical Documents (CTD) format as the requirement for
submission of medicines dossiers for Registration in 2019?
Is NMRA doing paper submission of registration applications in 2019?
Is NMRA doing paper submission of medicines dossiers in 2019?
Is NMRA doing on-line submission of registration applications in 2019? (Evidence: URL)
Is NMRA doing on-line submission of medicines dossiers in 2019? (Evidence: URL)
Does NMRA has on-line tracking system for applications under-going registration in 2019?
(Evidence: URL)
Do individuals have to come in person to track the applications under-going registration in
2019?
Does your NMRA have Guidelines, Standard Operating Procedure (SOPs) and Guidance
for registration of medicines in 2019? (Evidence)
Does your NMRA have National Medicines Policy (NMP) in 2019? (Evidence)
Does your NMRA have established timelines for registration of medicines in 2019? (Evidence)
Does your NMRAs have documented timelines in 2019? (Evidence)
Does your NMRA have systematic tracking in 2019? (Evidence)
Does your NMRA have electronic notification when registration is completed in 2019?
Does your NMRAs post list of registered medicines on on-line (website of NMRA) in 2019?
(Evidence: URL).
Does your NMRA have a paper publication of registered medicines in 2019?

Response

Remarks

(Yes / Non)

(Evidence)
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Does your NMRA have paper notification when registration of medicines is completed in
2019? (Evidence: Sample of the letter).
Do applicants have to come in person to be informed of the completion of the registration
of their products in 2019?
Does your NMRA registers medicines less than 100 days in 2019?
Does your NMRA register medicines between 100 – 200 days in 2019?
Does your NMRA register medicines between 200-365 days in 2019?
How long does it take before Registration Certificates are ready after the approval of the
Registration Committee (Median / Average time)?
Does your NMRA have backlogs of Registration Certificates to produce in 2019?
How many registration officers have your NMRAs?
How many of the registration officers have Bachelor of Pharmacy, B.Sc. level in Chemistry
and other related sciences?
How many of the registration officers have Master’s Degree in Pharmaceutical Science or
related sciences?
How many of the registration officers have Ph.D. degree in Pharmaceutical Science or
other related sciences?
How many of the registration officers that are female?
What is the Age bracket of the registration officers?
What is the average number of years they have worked in the registration Department / Directorate?
What is the average number of years they got employed in the NMRAs?
Is your NMRA at the Maturity level 2 or higher in Registration and Marketing Authorization
in 2019?
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APPENDIX B:
Tables 3 - 9 comparing the data from 2005, 2010 and 2017 reports
Table A3 Comparison of 2005, 2010 and 2017 data on Authority and Legal Forms of NMRAs in ECOWAS.
1. Authority and Legal Form of NMRAs
Status at Year Point (Autonomous =1, Not Autonomous = 0)

2005

2010

Y/N
(1/0) U=0

2017

Y/N
(1/0)
U=0

Country 1

Dept. within MoH

0

Dept. within MoH

0

Country 2

Dept. within MoH

0

Dept. within MoH

0

Country 3

U

0

Autonomous

1

Country 4

Dept. within MoH

0

Dept. within MoH

0

Country 5

Autonomous

1

Autonomous

1

Country 6

U

0

Dept. within MoH

0

U

0

Dept. within MoH

0

U

0

Dept. within MoH

0

Board under the control of MoH

0

Board under the control of MoH

0

Dept within the Min. of Public Health

0

Dept. within the Min. of Public
Health

0

Country 11

Autonomous

1

Autonomous

1

Country 12

Parastatal Agency
(+Professional Council
+Enforcement Agency)

0

Parastatal Agency
(+Professional Council +Enforcement Agency)

0

Country 13

Dept. within MoH

0

Country 14

Autonomous

1

Country 15

Dept. within MoH

0

Total

4

Country 7
Country 8
Country 9
Country 10

Problem to be addressed inappropriate legal status of
national medicines
regulatory authorities to carry out their
regulatory functions

Total
%

1
6.67

Total
%

2
13.33

%

Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in existence or they were not part of the sample size for those studies in the literature.

Table A4 Comparison of data on the existence of Marketing Authorization process in ECOWAS NMRAs in 2005, 2010 and
2017 reports.
2. Marketing Authorization by NMRA

26.67
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NMRA

2005

Y/U
(1/0)

Y/U
(1/0)

∑U=1

2010

Country 1

U

Yes

1

U

0

Country 2

U

Yes

1

Yes

1

Country 3

U

U

0

U

0

Country 4

U

Yes

1

Yes

1

Country 5

U

Yes

1

Yes

1

U

U

0

U

0

U

U

0

U

0

U

U

0

U

0

U

Yes

1

U

0

Country 10

U

Yes

1

U

0

Country 11

U

Yes

1

Yes

1

Country 12

U

Yes

1

U

0

Country 13

U

U

0

Yes

1

Country 14

U

U

0

U

0

Country 15

U

U

0

U

0

1

Total

8

Total

5

6.67

%

Country 6
Country 7
Country 8
Country 9

Problem to be Addressed
1. Inadequate human resource.
2. Inadequate legislation and regulation.
3. Inadequate tools - guidelines, SOPs not fully developed.
4. Inadequate funding

Total
%

53.33

2017

%

33.33

Yes = NMRA grants MA; Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory
authority was not in existence or they were not part of the sample size for those studies in the literature.

Table A5 Comparison of NMRAs in ECOWAS conducting GMP Inspection as found in the 2005, 2010 and 2017 reports.
3. Inspection of Manufacturing Sites by NMRA (Desktop review or actual inspection)

∑U=1

2010

Y=1
N=U=0
Y/N=0.5
(1/0)

Country 1

U

No

0

Country 2

U

Yes/No

U

NMRA

2005

2017

Y/U
(1/0)

U

U

0.5

Yes

1

U

U

U

U

U

Yes/No

0.5

Yes

1

Country 5

U

No

0

Yes

1

Country 6

U

U

U

U

U

Country 3
Country 4

Problem to be Addressed
1. Local production firms non-compliant with GMP / MRA not
trained in GMP.
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Country 7

U

U

U

U

U

Country 8

U

U

U

U

U

Country 9

U

Yes/No

0.5

U

U

Country 10

U

Yes/No

0.5

U

U

Country 11

U

Yes

1

Yes

1

Country 12

U

No

0

Yes

1

Country 13

U

U

U

Yes

1

Country 14

U

U

U

U

U

Country 15

U

U

U

U

U

1

Total

3

Total

6

6.67

%

20

%

40

Total
%

Yes = NMRA does the inspection; No = Another Institution does the inspection; Yes/No = NMRA and another Institution do the Inspection
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in existence or they were not part of the sample size for those studies in the literature.

Table A6 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports that conduct Quality Control of Medicines.
4. Quality Control of Medicines
NMRA

2005

∑U=1

2010

Y/N=U
(1/0)

2017

Y/U
(1/0)

Country 1

U

No

0

U

0

Country 2

U

No

0

Yes

1

Country 3

U

U

0

U

0

Country 4

U

No

0

Yes

1

Country 5

U

No

0

Yes

1

U

U

0

U

0

U

U

0

U

0

U

U

0

Yes

1

Country 9

U

Yes

1

Yes

1

Country 10

U

No

0

U

0

Country 11

U

Yes

1

Yes

1

Country 12

U

No

1

Yes

1

Country 13

U

U

0

Yes

1

Country 6
Country 7
Country 8

Problems to be Addressed
1. Weak Quality Control (need to re-equip the laboratories;
strengthen QC management systems.
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Country 14

U

U

0

U

0

Country 15

U

U

0

U

0

1

Total

3

Total

8

%

20

%

Total
%

6.67

53.33

Yes = NMRA does the Quality Control; No = Another Institution does the Quality Control or it is not done at all.
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in existence or they were not part of the sample size for those studies in the literature.

Table A7 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports with Quality Management System.
5. Quality Management System
Y/N=U
(1/0)

2017

Y/U
(1/0)

U

0

Yes

1

U

No

0

Yes

1

Country 3

U

U

0

Yes

1

Country 4

U

U

0

Yes

1

Country 5

U

Being drafted

0.5

U

0

Country 6

U

U

0

U

0

Country 7

U

U

0

U

0

U

U

0

U

0

U

No

0

U

0

Country 10

U

No

0

U

0

Country 11

U

Being drafted

0.5

U

0

Country 12

U

Yes, for administrative processes

0.5

U

0

Country 13

U

U

0

U

0

Country 14

U

U

0

U

0

Country 15

U

U

0

U

0

Total

1

Total

1.5

Total

4

%

6.67

%

10

%

NMRA

∑U=1

2010

Country 1

U

Country 2

Country 8
Country 9

2005

Problem to be Addressed
No information on Quality Management Systems of
Members State of ECOWAS in the 2005 report

26.67
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Yes = QMS exists; No = QMS does not exist; anything in between = 0.5.
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in existence or they were not part of the sample size for those studies in the literature.

Table A8 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports with Information Management System.
6. Information Management System (functional Websites: share info. with stakeholders)
2005

∑U=1

Country 1

U

Country 2

U

Country 3

2010

2017

∑U=1

0

U

No

0

U

U

U

0

U

Country 4

U

No

0

U

Country 5

U

Yes

1

U

Country 6

U

U

0

U

U

U

0

U

U

0

U

U

0

Country 10

U

No

0

U

Country 11

U

Yes

1

U

Country 12

U

Yes

1

U

Country 13

U

U

0

U

Country 14

U

U

0

U

Country 15

U

U

0

U

Total

1

Total

3

Total

1

%

6.67

%

20

%

6.67

Country 7
Country 8
Country 9

Problem to be Addressed
1. Weak Information Management System and
lack of access to independent information

No information in the
2017 research paper on
Information Management
Systems of the Sub-Saharan Countries

Yes = functional website; No = No functional website; Yes/No = development of a website is on-going
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in existence or they were not part of the sample size for those studies in the literature.

Table A9 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports engaging in harmonization and international
collaboration.

U
U
U
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7. Harmonization and International Cooperation
2005

2010

2017

Country 1

U

U

U

0

Country 2

U

U

Yes

1

Country 3

U

U

U

0

Country 4

U

U

Yes

1

Country 5

U

U

Yes

1

Country 6

U

U

Yes

1

U

Yes

1

U

Yes

1

U

Yes

1

Country 7
Country 8
Country 9

Problem to be Addressed
1. Lack of technical cooperation networking between
MRAs

U
U
U

information on harmonization
and International Cooperation
not captured by the 2010 report of the WHO

Country 10

U

U

Yes

1

Country 11

U

U

Yes

1

Country 12

U

U

Yes

1

Country 13

U

U

Yes

1

Country 14

U

U

Yes

1

Country 15

U

U

Yes

1

Total

1

Total

1

Total

13

%

6.67

%

6.67

%

86.67

Yes = participating in harmonization initiative; No = Not participating in harmonization initiative
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in existence or they were not part of the sample size for those studies in the literature.

